What is it about?
The paper focuses on a clinical trial that meticulously compares the safety and effectiveness of Unani formulations and PUVAsol in addressing non-segmental vitiligo, a long-lasting autoimmune pigmentary disorder distinguished by patches and macules of reduced pigmentation. The trial involved 82 participants aged between 18 and 40 years, with the primary assessment based on the variation in vitiligo area scoring index (VASI) observed at weeks 4, 8, 12, and 16. The study ultimately deduced that both treatments exhibited comparable efficacy and were well-tolerated among patients with non-segmental vitiligo.
Photo by Hanen BOUBAHRI on Unsplash
Why is it important?
This paper holds significant importance as it presents compelling scientific evidence regarding the safety and effectiveness of Unani formulations as compared to PUVAsol in the treatment of non-segmental vitiligo, a widespread and emotionally distressing condition. The study's discoveries have the potential to empower physicians and patients with valuable information when considering treatment options for vitiligo.
Read the Original
This page is a summary of: A non-inferiority randomized controlled clinical trial comparing Unani formulations & PUVAsol in non-segmental vitiligo, Journal of Complementary and Integrative Medicine, June 2021, De Gruyter, DOI: 10.1515/jcim-2021-0057.
You can read the full text:
The following have contributed to this page